Inquiry
Form loading...

3-Amino-1-adamantanol 702-82-9

IUPAC Name:3-aminoadamantan-1-ol
Molecular Weight:167.25
Molecular Formula:C10H17NO
Quality Standard:In House

    Product Specification

    Appearance: Off-White to white powder
    Identification:GC: The retention time is in accordancewith the standard.
    Water: ≤1.0%
    Residue on ignition: ≤0.1%
    Melting range: 266℃-271℃
    Related substances: Max. Single impurity≤0.5%、Total impurities≤1.5%
    Purity: ≥98.5%

    description1

    PRODUCT DESCRIPTION

    Vildagliptin is a selective, competitive, and reversible inhibitor of DPP24; GLP-1 and GIP are important hormones that maintain blood glucose levels and have intestinal proinsulin effects; GIP has impaired insulin secretion in type 2 diabetic patients; only GLP-1 can promote insulin secretion by acting on the receptor on the pancreatic beta cell membrane; GLP-1 can also inhibit the secretion of glucagon and inhibit gastric emptying, which increases satiety (inhibits appetite); DPP24 binds to proteins in many tissues, including the pancreatic ducts, lymphocytes, and endothelial cells. It can quickly inactivate GLP-1 by hydrolyzing its N-terminal second alanine. This product inhibits the activity of the enzyme by combining with DPP24 to form a DPP24 complex.By hydrolyzing GLP-1's second alanine at the N-terminus, it can swiftly render it inactive. This product forms a DPP24 complex with DPP24, which suppresses the enzyme's function. It lowers blood sugar via raising GLP-1 concentration, encouraging pancreatic beta cells to produce insulin, and lowering glucagon concentration. Furthermore, it doesn't significantly affect weight.

    According to pharmacokinetic tests conducted on healthy subjects, this medication has an 85% absorption rate, a 4% to 17% protein binding rate, and a Tmax of 1-2 hours after oral administration. Blood drug concentration and dosage have a linear relationship when the dosage is between 25 and 200 mg, with a half-life of 1.5 to 4.5 hours. The length of inhibition varies depending on the dose, but when given at a single dose of 25–200 mg, the inhibition rate of DPP-IV in plasma can reach over 90% in 30–60 minutes. DPP-IV has 12-hour inhibition rates of 70% and 90% at 50 and 100 mg, respectively, and a 24-hour inhibition rate of 40% in the 100 mg group.The majority of this product's metabolism (55%) occurs through the hydrolysis of cyanide groups. Furthermore, very few pharmaceuticals are processed by cytochrome P450 enzymes, with 22% of medicines being eliminated through the kidneys as prototype drugs. Nevertheless, this product does not stimulate or inhibit this enzyme. Patients with liver and kidney impairment did not require dosage adjustments, nor was there any drug accumulation during multiple dose administration. Food had no effect on the pharmacokinetic outcomes either.